Zacks Investment Research
04 Dec 2025, 17:46 UTC · 47w ago
IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?
Impact · against what's priced in
IDEXX Laboratories demonstrates strong operational momentum with growth in recurring revenue and installed base, but much of this is likely reflected in the stock's massive 75.6% year-to-date rally. The data confirms a high-performing business model but offers little in the way of new catalysts to drive further upside from current levels.
- IDXX+0.20
No priced-in read yet
- In context
The company's Companion Animal Group Diagnostics saw organic recurring revenue growth exceed 10% in Q3 2025, supported by a 10% increase in its active premium instruments installed base.
Read from the article alone
Search tags
